MedTrace Logo

An Evaluation Of PF-03715455 In Moderate To Severe Chronic Obstructive Pulmonary Disease

NCT02366637 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 13

Last updated 2016-07-06

Study results available
· View outcomes & findings →

Summary

This study proposes to evaluate the safety and efficacy of PF-03715455 in subjects with moderate to severe Chronic Obstructive Pulmonary Disorder.

Conditions

  • Pulmonary Disease, Chronic Obstructive

Interventions

DRUG

Placebo

Orally inhaled placebo twice a day (BID) for 4 weeks

DRUG

PF-03715455

680 micrograms BID, Orally inhaled PF-03715455 for 4 weeks

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
40 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-01-31
Primary Completion
2015-05-31
Completion
2015-05-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02366637 on ClinicalTrials.gov